Assignee: Dana-Farber Cancer Institute

Location: Boston, MA
No. of patents: 132

Number	Title	Issue Date
8138314	Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.	03/20/2012
8071294	Cancer therapy sensitizer The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucl...	12/06/2011
8034791	Activation of Egr-1 promoter by DNA damaging chemotherapeutics The present invention relates to methods of inducing expression of a polynucleotide encoding a therapeutic polypeptide, e.g., TNF-α, in a cell comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding ...	10/11/2011
7919310	Constitutive gene expression in conjunction with ionizing radiation The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are ...	04/05/2011
7858742	Lymphoma associated molecules and uses therefor The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL ...	12/28/2010
7838512	DNA damaging agents in combination with tyrosine kinase inhibitors Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit ...	11/23/2010
7838220	T cell regulatory genes associated with immune disease A genetic locus and corresponding family of proteins associated with regulation of immune development, function, and cell survival are provided. The locus comprising the TIM family is genetically associated with immune dysfunction, including atopy, autoimmunity, inf...	11/23/2010
7754463	Inhibitors of USP1 Deubiquitinating Enzyme Complex The invention provides compositions and methods used to inhibit USP1 deubiquitinase activity and to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be used to treat or prevent cancer, bone marrow failure, and damage to cells or DNA resulting from ...	07/13/2010
7700102	Nucleic acids encoding CD100 molecules Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules ha...	04/20/2010
7658923	Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration....	02/09/2010
7638272	Cancer therapy sensitizer The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucl...	12/29/2009
7635708	Methods and pharmaceutical compositions for inhibiting tumor cell growth The present invention is based on the finding that activation of PPARγ plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPARγ agonists, such as thiazolidinedione ligands (TZDs), ...	12/22/2009
7595154	Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides metho...	09/29/2009
7592317	Constitutive gene expression in conjuction with ionizing radiation The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are ...	09/22/2009
7525011	Transgenic cancer models in fish The present invention provides transgenic fish whose genome has stably-integrated therein an oncogene operably linked to a promoter. Methods of making the transgenic fish and methods for their use are also provided. In one embodiment, the transgenic fish may advanta...	04/28/2009
7470428	Compositions and methods related to TIM-3, a Th1-specific cell surface molecule The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is r...	12/30/2008
7459544	Nucleic acids encoding B7-2 fusion proteins Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a por...	12/02/2008
7396678	Method for detection of alterations in the DNA mismatch repair pathway We have now discovered that eukaryotes, including mammals, have a DNA mismatch repair pathway analogous to the pathway that exists in bacteria. Defects or alterations in this mismatch repair pathway in a mammal, such as a human, will result in the accumulation of un...	07/08/2008
7354588	Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is direc...	04/08/2008
7256197	Methods for synthesis of diarylmethanes The present invention relates to dihydrofolate reductase inhibitors having an aromatic group and a heteroaromatic group linked by a methylene group; methods of preparation of dihydrofolate reductase inhibitors that include metal mediated cross coupling of an aromati...	08/14/2007
7250291	Tumor antigens and uses thereof The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing...	07/31/2007
7250283	PGC-1 isoforms and uses therefor The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vecto...	07/31/2007
7247438	Methods of identifying agents which enhance caspase activity Methods for identifying agents which enhance the activity of a caspase according to the invention are described, as well as methods for enhancing caspase activity and methods for enhancing apoptosis in a lymphocyte. ...	07/24/2007
7247297	Use of DF3/MUC1 regulated expression in gene therapy The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tum...	07/24/2007
7223411	Herpesvirus replication defective mutants A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eli...	05/29/2007
7198788	Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26. Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration....	04/03/2007
7186697	Nucleic acid delivery system, methods of synthesis and use thereof A nucleic acid delivery system is described. The delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be ...	03/06/2007
7176186	Stimulation of cell-mediated immune responses by targeted particulate genetic immunization The present invention relates to various methods of genetic immunization for the purpose of providing antigen-specific immunity in a mammalian host, including a human host. The invention is based on the ability to direct particulate polynucleotides which express an ...	02/13/2007
7118738	Recombinant pox virus for immunization against MUC1 tumor-associated antigen Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-...	10/10/2006
7112420	Lymphoma associated molecules and uses therefor The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nu...	09/26/2006
7105328	Methods for screening for compounds that modulate pd-1 signaling Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule Further disclosed are a vaccine and also other compositions which con...	09/12/2006
7105655	Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain The present application is directed to stabilized envelope glycoprotein trimers. The trimers are stabilized by introducing disulfide bonds at certain sites in the gp41 ectodomain. DNA molecules encoding such trimers can be used to generate an immunogenic reaction.	09/12/2006
7056911	Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases ...	06/06/2006
6989386	Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same In one embodiment, the present invention relates to a new class of ammonium salts of Nδ-acyl derivatives of Nα-(4-amino-4-deoxypteroyl)-L-ornithine compounds having a structure according to formula II-IV. Formula II has the structure o...	01/24/2006
6872391	PGC-1, a novel brown fat PPARγ coactivator The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipog...	03/29/2005
6870040	Nucleic acid sequence encoding lymphoma associated molecule BAL The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL ...	03/22/2005
6719972	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an ...	04/13/2004
6608180	B7-specific antibodies Novel structural forms of T cell costimulatory molecules are described. These structural forms comprise a novel structural domain or have a structural domain deleted or added. The structural forms correspond to naturally-occurring alternatively spliced fo...	08/19/2003
6605279	Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands Disclosed is a composition for inhibiting the interactions of B7-1 and B7-2 with their natural ligands. Such compositions comprise an antibody specific for B7-2 and an antibody specific for B7-1, in a pharmaceutically acceptable carrier. The composition m...	08/12/2003
6576754	CD100 antigen and uses therefor Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel m...	06/10/2003

«First «Previous1 2 3 4 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Dana-Farber Cancer Institute